Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
